

Synthesis of nimbolide and its analogues and their application as poly(ADP-ribose) polymerase-1 trapping inducers

Larisa P. Pop

The Shenvi Lab, The Scripps Research Institute



@Shenvi_Lab
shenvilab.org



Group Meeting
January 13th, 2024

Introduction

nature synthesis

Article

<https://doi.org/10.1038/s44160-023-00437-w>

Synthesis of nimbolide and its analogues and their application as poly(ADP-ribose) polymerase-1 trapping inducers

Received: 27 December 2022


Accepted: 11 October 2023

Published online: 27 November 2023

 Check for updates

Heping Deng^{1,3}, Hejun Deng  ^{1,3}, Chiho Kim  ^{1,2}, Peng Li  ¹, Xudong Wang^{1,2}, Yonghao Yu  ^{1,2}✉ & Tian Qin  ¹✉


Nimbolide, a ring seco-C limonoid natural product, was recently found to inhibit the poly(ADP)-ribosylation (PARylation)-dependent ubiquitin E3 ligase RNF114. In doing so, it induces the ‘supertrapping’ of both PARylated PARP1 and PAR-dependent DNA-repair factors. PARP1 inhibitors have reshaped the treatment of cancer patients with germline *BRCA1/2* mutations partly through the PARP1 trapping mechanism. To this end, modular access to nimbolide analogues represents an opportunity to develop cancer therapeutics with enhanced PARP1 trapping capability. Here we report a convergent synthesis of nimbolide through a late-stage coupling strategy. Through a sulfonyl hydrazone-mediated etherification and a radical cyclization, this strategy uses a pharmacophore-containing building block and diversifiable hydrazone units to enable the modular synthesis of nimbolide and its analogues. The broad generality of our synthetic strategy allowed access to a variety of analogues with their preliminary cellular cytotoxicity and PARP1 trapping activity reported.



Education and Career

- BSc degree in chemistry at the University of Science and Technology of China
- PhD at Boston University (*Advisor: Prof. J. Porco*)
- Postdoctorate studies at Scripps Research (*Advisor: Prof. P. Baran*)
- Assistant professor at UT Soutwestern since 2018

Nimbolide, a terpene natural product




- Nimbolide is a natural product obtained from the leaves and flowers of Neem.
- It has been shown to possess multiple therapeutic effects, like anti-malaria and anti-bacterial.
- It also inhibits tumorigenesis and metastasis without causing any toxicity around a wide range of cancers.



Neem tree leaves (*Azadirachta indica*)

DNA damage: an overview



- SSB: single-stranded DNA break.
- PARP: it is a protein that stands for poly-ADP ribose polymerase. It helps damaged cells to repair themselves. As a cancer treatment, PARP inhibitors stop the PARP from doing its repair work in cancer cells and the cell dies.
- XRCC1: it is a protein involved in DNA damage repair.
- RNF114: this protein is a E3 ubiquitin ligase, involved in protein homeostasis and removal of unwanted or damaged proteins.

Available on Sigma Aldrich!




Products

Type in Product Names, Product Numbers, or CAS Numbers to see suggestions.



US

EN

[Back](#) [Home](#) > [Natural Products](#) > SMB00586[All Photos \(1\)](#)**SMB00586** ▶ **Sigma-Aldrich®**

Nimbulide

 (0) [Write a review](#)from *Azadirachta indica*, ≥98%

Synonym(s):

NSC-309909

Empirical Formula (Hill Notation):

C₂₇H₃₀O₇


Documents

[SDS](#)[COO/COA](#)[Specification Sheet](#)[Copy Link](#)[Email](#)[Sign In to View Organizational & Contract Pricing](#)


SKU	Pack Size	Availability	Price	Quantity
SMB00586-5MG	5 mg	Available to ship on January 04, 2024 Details...	\$493.00	- + i

[Request a Bulk Order](#)[Add to Cart](#)

Extraction and Purification of Nimbolide



Pharmacophore meets strategy




nimbolide
pharmacophore

The enone moiety and lactone ring of nimbolide were identified as the essential pharmacophore for the observed activity




Pharmacophore meets strategy



nimbolide
pharmacophore


The enone moiety and lactone ring of nimbolide were identified as the essential pharmacophore for the observed activity




A

B


Let's talk about their starting material




First-generation optimization:




Let's talk about their starting material




First-generation optimization:




Let's talk about their starting material




Let's talk about their starting material




Ozonolysis of phenols




Synthesis of the pharmacophore-contained building




Synthesis of the pharmacophore-contained building





Synthesis of the pharmacophore-contained building





Synthesis of the pharmacophore-contained building





Synthesis of the pharmacophore-contained building





Synthesis of the pharmacophore-contained building




Synthesis of the pharmacophore-contained building




Synthesis of the pharmacophore-contained building




Synthesis of the diversifiable unit




Synthesis of the diversifiable unit




Synthesis of the diversifiable unit




Rautenstrauch Rearrangement



Towards Nimbolide Endgame



Model study for cyclization to nimbolide




MHAT: decomposition

AIBN, Bu_3SnH in toluene or benzene: the major product was **c**, trace of **1**

AIBN, Bu_3SnH , PhF: **1** 24%

AIBN, Bu_3SnH , C_6F_6 : **1** 47%

Model study for cyclization to nimbolide




MHAT: decomposition

AIBN, Bu₃SnH in toluene or benzene: the major product was c, trace of 1


AIBN, Bu₃SnH, PhF: 1 24%

AIBN, Bu₃SnH, C₆F₆: 1 47%


Nimboldine Endgame




Late stage diversifications




Late stage diversifications




Late stage diversifications






Cytotoxicity and studies on the analogues


Nimbotide analogues with a five-membered C ring and downstream natural products




27



28




29




30 R = H

31 R = OMe

32 R = OTBS



44










45

Downstream natural products	
Compound	IC ₅₀ (μM)
22	> 10
23	> 10
24	> 10
25	> 10
26	> 10

Intermediate/related structure	
Compound	IC ₅₀ (μM)
1	0.34 ± 0.05
12	> 10
19	0.23 ± 0.04
44	0.88 ± 0.11
45	> 10


Five-membered C ring	
Compound	IC ₅₀ (μM)
27	1.45 ± 0.19
28	0.98 ± 0.13
29	0.21 ± 0.05
30	0.30 ± 0.05
31	0.27 ± 0.05
32	0.079 ± 0.01

Nimbolide analogues with a six-member C ring





Six-membered C ring	
Compound	IC ₅₀ (μ M)
21	0.49 ± 0.04
34	0.49 ± 0.07
36	0.17 ± 0.03
35	0.16 ± 0.04
37	0.11 ± 0.03
38	0.18 ± 0.04
33	0.80 ± 0.09
39	0.88 ± 0.11
41	0.16 ± 0.03
40	0.20 ± 0.05
42	0.17 ± 0.04
43	0.05 ± 0.04

PARP1 trapping studies and selected analogues



Is the PAPR1 still efficiently trapped at the DNA-damage site by the nimblolide analogues?

Yes!



Thank you for the attention



Grazie dell'attenzione



Mulțumesc pentru atenția



Larisa P. Pop

The Shenvi Lab, The Scripps Research Institute